ArticleCureus2025
Prevalence of Psoriatic Arthritis and Its Risk Factors Among Patients With Psoriasis in a Tertiary Care Center in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that develops in a subset of psoriasis patients, often leading to functional impairment and comorbid conditions. Early detection and management of PsA are essential for improving patient outcomes. This study aimed to (1) determine PsA prevalence among psoriasis patients at a tertiary care center in Jeddah, Saudi Arabia; (2) identify risk factors for PsA development; and (3) describe clinical PsA subtypes. Methods In this retrospective cross-sectional study, 414 psoriasis patients were evaluated using electronic medical records and supplementary telephone interviews. A nested case-control analysis compared PsA cases (n=53) to psoriasis-only controls (n=354). Descriptive statistics summarized prevalence and subtype distribution, while logistic regression assessed associations between PsA and potential risk factors. Results PsA prevalence in our population was 13%, with a female predominance, 36 (67.9%). Asymmetric oligoarticular arthritis, 20 (39.2%), was the most frequent subtype, followed by symmetric polyarthritis, 15 (29.4%). Nail involvement was present in 25 (52.1%) of PsA patients. Cardiovascular (47.2% vs. 35.6%) and psychiatric comorbidities (11.3% vs. 5.1%) were more common in PsA patients. Logistic regression identified family history of PsA (OR = 7.8; 95% CI: 1.44-42.2) and psychiatric comorbidities (OR = 4.5; 95% CI: 1.17-17.04) as significant predictors of PsA. Conclusion PsA affects a notable proportion of psoriasis patients and is associated with higher rates of cardiovascular and psychiatric comorbidities. Asymmetric oligoarthritis predominated, and family history emerged as a strong predictor. These findings underscore the need for early screening and multidisciplinary management. Larger multicenter studies are warranted to validate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.